IDEAYA Biosciences (30J) Stock Overview

A precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. More details

30J fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 85.1% below our estimate of its fair value

Revenue is forecast to grow 41.28% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

30J Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

IDEAYA Biosciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for IDEAYA Biosciences
Historical stock prices
Current Share Price	US$23.78
52 Week High	US$32.60
52 Week Low	US$18.30
Beta	-0.049
1 Month Change	-0.084%
3 Month Change	-16.27%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	33.60%
Change since IPO	140.20%

Recent updates

Shareholder Returns

	30J	DE Biotechs	DE Market
7D	-2.3%	-3.1%	-2.9%
1Y	n/a	-8.0%	-0.8%

Return vs Industry: Insufficient data to determine how 30J performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 30J performed against the German Market.

Price Volatility

Is 30J's price volatile compared to industry and market?
30J volatility
30J Average Weekly Movement	7.6%
Biotechs Industry Average Movement	8.8%
Market Average Movement	5.9%
10% most volatile stocks in DE Market	13.0%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: 30J has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 30J's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2015	145	Yujiro Hata	www.ideayabio.com

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial.

IDEAYA Biosciences, Inc. Fundamentals Summary

How do IDEAYA Biosciences's earnings and revenue compare to its market cap?
30J fundamental statistics
Market cap	€2.14b
Earnings (TTM)	-€121.28m
Revenue (TTM)	€195.06m

10.8x

P/S Ratio

-17.3x

P/E Ratio

Is 30J overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
30J income statement (TTM)
Revenue	US$225.27m
Cost of Revenue	US$339.54m
Gross Profit	-US$114.27m
Other Expenses	US$25.79m
Earnings	-US$140.06m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-1.59
Gross Margin	-50.73%
Net Profit Margin	-62.17%
Debt/Equity Ratio	0%

How did 30J perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/10 22:08
End of Day Share Price	2026/06/10 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IDEAYA Biosciences, Inc. is covered by 31 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Madhu Kumar	Baird
Zhiqiang Shu	Berenberg
Suranjit Mukherjee	BTIG

IDEAYA Biosciences (30J) Stock Overview

Rewards

Risk Analysis

IDEAYA Biosciences, Inc. Competitors

Biotest

Biotest GmbH KGaA

2invest

Formycon

Price History & Performance

Recent News & Updates

IDEAYA Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

IDEAYA Biosciences And Servier Present Complete Data From Phase 2/3 OptimUM-02 Trial Of Darovasertib Combination In First Line HLAA2:01 Negative Metastatic Uveal Melanoma

Ideaya Biosciences Initiates New Drug Application Submission for Darovasertib Combination

IDEAYA Biosciences, Inc., Annual General Meeting, Jun 16, 2026

Ideaya Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial of Darovasertib in Combination with Crizotinib in First-Line Hla-A*02:01-Negative Metastatic Uveal Melanoma

Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE574, A Potential First-In-Class Dual Inhibitor Of KAT6/7 To Target Multiple Solid Tumor Indications Including Breast, Prostate, CRC, And Lung Cancer

Recent updates

IDEAYA Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

IDEAYA Biosciences And Servier Present Complete Data From Phase 2/3 OptimUM-02 Trial Of Darovasertib Combination In First Line HLAA2:01 Negative Metastatic Uveal Melanoma

Ideaya Biosciences Initiates New Drug Application Submission for Darovasertib Combination

IDEAYA Biosciences, Inc., Annual General Meeting, Jun 16, 2026

Ideaya Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial of Darovasertib in Combination with Crizotinib in First-Line Hla-A*02:01-Negative Metastatic Uveal Melanoma

Ideaya Biosciences Announces First-Patient-In For Phase 1 Trial Of IDE574, A Potential First-In-Class Dual Inhibitor Of KAT6/7 To Target Multiple Solid Tumor Indications Including Breast, Prostate, CRC, And Lung Cancer

IDEAYA Biosciences, Inc. Announces First-Patient-In For Phase 1 Combination Study Of Ide849 And Ide161

Independent Director recently bought €1.4m worth of stock

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, Potential PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific Top1 ADC

IDEAYA Biosciences, Inc. Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer

Insufficient new directors

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (Optimum-02) of Darovasertib in Combination with Crizotinib in First-Line HLA A2-Negative Metastatic Uveal Melanoma

IDE034, a Bispecific ADC Licensed by Biocytogen Pharmaceuticals (Beijing) Co., Ltd to IDEAYA Biosciences, Inc, Receives FDA IND Clearance

Ideaya Biosciences, Inc. Announces Ind Clearance for Ide034, A Potential First-In-Class Bispecific B7h3/Ptk7 Top1 Adc Targeting Multiple Solid Tumor Types

New major risk - Revenue and earnings growth

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in A Proffered Paper Oral Presentation At ESMO 2025

IDEAYA Biosciences Announces Positive Data from Phase 1/2 Combination Trial of IDE397, a Potential First-In-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer

IDEAYA Biosciences, Inc. Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397

IDEAYA Biosciences, Inc. Announces IND Submission for IDE892, A Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors

Ideaya Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma At the 2025 Society for Melanoma Research Congress

IDEAYA Biosciences, Inc. Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 3000 Growth Index

Ideaya Biosciences, Inc. Appoints Joshua Bleharski as Chief Financial Officer

IDEAYA Biosciences, Inc., Annual General Meeting, Jun 24, 2025

IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma

IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer

IDEAYA Biosciences, Inc. Announces Resignation of Susan L. Kelley from the Board

IDEAYA Biosciences, Inc. Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

Ideaya Biosciences, Inc. Announces the Appointment of Joshua Bleharski as Chief Financial Officer

IDEAYA Biosciences, Inc. Announces IDMCRecommendation of Move-Forward Dose in Part 2A of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

Ideaya Biosciences, Inc. Announces First-Patient-In for Phase 1 Clinical Trial Evaluating Ide161 in Combination with Keytruda®? (Pembrolizumab) in Patients with Endometrial Cancer

IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer

Third quarter 2024 earnings released: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023)

IDEAYA Biosciences, Inc. Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

IDEAYA Biosciences, Inc. Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel

IDEAYA Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $263.000016 million.

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 3000E Value Index

IDEAYA Biosciences, Inc Announces Resignation of Jason Throne as Chief Legal Officer and Secretary, Effective July 11, 2024

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer

IDEAYA Biosciences, Inc. Announces Clinical Program Updates for Ide397 A Potential First-In-Class Phase 2 Mat2a Inhibitor Targeting MTAP-Deletion Solid Tumors

IDEAYA Biosciences, Inc. Announces Results for darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma At Asco and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study

IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024

IDEAYA Biosciences, Inc., Annual General Meeting, May 31, 2024

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Full year 2023 earnings released: US$1.96 loss per share (vs US$1.42 loss in FY 2022)

New major risk - Shareholder dilution

IDEAYA Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline

IDEAYA Biosciences, Inc. Announces Resignation of Paul A. Stone as Chief Financial Officer

IDEAYA Biosciences, Inc. Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo) Adjuvant Uveal Melanoma

IDEAYA Biosciences, Inc. Appoints Andres Ruiz Briseno as Principal Accounting Officer

IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types

IDEAYA Biosciences, Inc. Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma

IDEAYA Biosciences, Inc. Announces Board Appointments

IDEAYA Biosciences, Inc Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161

IDEAYA Biosciences, Inc. Appoints Darrin M. Beaupre as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline

IDEAYA Biosciences, Inc. Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors

IDEAYA Biosciences, Inc. Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma

IDEAYA Biosciences, Inc. Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma

IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-In-Class Pol Theta Helicase Inhibitor Development Candidate

Second quarter 2022 earnings released: US$0.57 loss per share (vs US$0.33 loss in 2Q 2021)